Introduction
potential has yielded promising results (reviewed in [1, 2] [3] [4] [5] [6] [7] . Although based on different study selection criteria, these analyses were in agreement that administration of autologous cells in the heart is safe, and that it causes an improvement, although modest, in primary clinical end-points such as ejection fraction, end-systolic volume and infarct scar size.
A possible explanation for the null or modest effect of BMCs administration in patients may arise from the use of non-selected cellular fractions [8] . In fact, it has been suggested that administration of non-selected BMCs may have an antagonistic, 'Januslike', effect resulting from the secretion of cytokines having a provasculogenic, but also pro-inflammatory and pro-atherogenic effects [9] . Thus, while BMCs injection has been reported to better preserve heart function compared to other progenitor cells types such as mesenchymal stem cells, skeletal myoblasts and fibroblasts [10] , the use of selected progenitors may prevent possible adverse consequences such as inflammatory and atherogenic response (discussed in [11] ).
Endothelial progenitors cells (EPCs) have been found in the human umbilical cord blood (UCB), peripheral blood and the adult bone marrow (BM) (reviewed in [12]). Recently, two distinct EPCs populations have been identified and characterized, the endothelial colony forming cells (ECFCs) (also named endothelial outgrowing cells, OECs, or 'late' EPCs) that do not express the CD45 pan-haematopoietic marker, and CD45
ϩ CD133 ϩ CD34 ϩ - [16, 18] , CFU-ECs have modest or null proliferation ability and stimulate blood vessels formation in a paracrine way [18] , by secreting an array of pro-angiogenic and pro-inflammatory cytokines [19] . [20] ). In fact, the benefits of isolated human CD34 ϩ and CD133 ϩ cells administration have been validated in MI [21] [22] [23] [24] [25] and hind limb ischemia or cutaneous wounds [26] [27] [28] [29] [30] [8, 31] and a higher selectivity for myocardial homing after intracoronary administration into patients [32] [33] [34] 
derived EPCs that have been named colony forming unit-endothelial cells (CFU-ECs or 'early' EPCs) [13-17]. The two cell types differ in their clonogenic capacity as well as their ability to contribute to neo-vascularization process in vivo; while ECFCs have high colonogenic activity and participate to formation of blood vessels

A definitive consensus about the clinical use of one or the other EPC type has not been reached. In fact, despite preclinical studies have highlighted lineage distinctions and different biological properties of CFU-ECs and ECFCs, the CD34 and CD133 antigens remain the reference markers to be used to isolate EPCs for clinical trials, irrespective of their CD45 expression (discussed in
GMP process and quality control (QC) testing
A detailed description of our GMP program and QC testing of CD133 CBMPs is described in the supplementary online section. [44, 45] .
In vitro experiments
Statistical analysis
All data are expressed as mean Ϯ S.E.M.; 2-tailed unpaired Student's t-test
was performed with GraphPad statistical software, and a probability value of P Ͻ 0.05 was considered statistically significant.
Results
From purification to quality control and certification of CB CD133 CBMPs production procedure 
Magnetic purification by CliniMACS was chosen as it is performed with clinical grade reagents that are routinely used for purification of haematopoietic stem cells in haematological transplantation
settings [46, 47] , and because it was safely used in previous studies to produce CD133 ϩ cells for the treatment of patients with cardiac ischemia [35, 38, 40] . The GMP-compliant CD133 CBMPs production process was organized and accomplished according to the scheme presented in Fig. 1 . In this scheme, the QC testing actions, the locations of each action and the responsibility of the actions at each step are represented. Table 1 Fig. 3(A) . Briefly, the cells were grown in culture with mitogenic cytokines [29] for a period of 5 days, after which they were counted. After counting, cells were plated under differentiation conditions to assess the formation of EPC (CFU-EC) early colonies [15, 42, 48] . According to Seeger et al. [49] (Fig. 3B, C) showed that CD133 CBMPs stored in these media had a proliferation rate that was comparable to that shown by CBderived freshly isolated CD133 ϩ cells under the same culture conditions (Fig. 3C) .
Both in animal models [21] and in patients [35, 39] [15, 42] . The results showed the development of large cellular clusters taking up Ac-LDL-DiI and stained with UEA-1 lectin [48] (Fig. 4) , typically resembling CFU-EC colonies [15] . [23, 28] (Fig. 7) . The biological quality of BM CD133 CBMPs was then functionally assessed by in vitro tests that were performed according to the procedure established for CB-derived CD133 ϩ shown in Fig. 3 (Fig. 8A) (Fig. 8D) . [50] . [52] [53] [54] (also discussed in [41, 55, 56] ). A second possibility, not necessarily alternative to the previous, is the use of strategies that maximize CBMPs reproducibility, safety and efficacy [49] .
CD133 CBMPs were injected in the ischemic limbs, a significant increase in perfusion ratio compared to saline-injected mice was observed at the same time-points. Morphometric analysis was performed on adductor muscle sections at day 14 after femoral artery dissection. Both the capillary and the arterioles density (Fig. 5B and C, respectively) were significantly increased by CD133 CBMP injection.
Translation of isolation procedures to BM samples for autologous transplantation in patients affected by myocardial ischemia: release quality control and in vitro proofs of principle
SOPs established to produce CB-derived CD133 CBMPs were translated to production of clinical grade CD133 CBMPs from BM of three patients undergoing a phase II clinical trial of CD133 ϩ cells intramyocardial administration, which has been recently approved by Italian Regulatory Agency. This trial is currently being carried at Centro Cardiologico Monzino. Translation of GMP procedures to obtain BM-derived CD133 CBMPs from CB was not immediate and required suitable validation runs. In fact, differences in the stem cells sources may cause (1) a different recovery of MNCs after Ficoll gradient centrifugation and (2) a different purity of yielded cells due to differences in the CD133 expression level in BM compared to CB stem cells. To address these issues we calculated the percentage of MNCs loss after CB and BM Ficoll gradient centrifugation. As shown in Table S1, a higher cellular loss was observed using BM compared to CB. The difference in MNCs recovery was not statistically significant and a high variability was observed between different samples. We also calculated the mean fluorescence
Fig. 4 In vitro CD133 CBMPs differentiation. After 5 days in expansion medium, X-VIVO or 7.5% HSA saline solution stored cells were plated onto fibronectin-coated dishes to promote the formation of CFU-EC EPC colonies. (A) shows the morphologic appearance of a CFU-EC cluster and the histochemical detection by fluorescence microscopy of AC-LDL-DiI uptake (red fluorescence), UEA-1-FITC lectin (green fluorescence
)
(A). In these experiments it was found that, analogous to CB, BM-derived CD133 CBMPs formed CFU-EC colonies (not shown). The endothelial-like phenotype of cells composing these colonies was confirmed by detection of the endothelial marker vWF by immunofluorescence
Discussion
Therapeutic use of EPCs has been suggested as a promising approach to induce neo-vascularization in ischemic diseases
From GMP compliance to proofs of principle: 'release' and 'potency' validation levels for standardization of CBMPs production process for cardiovascular therapy (Fig. 9) .
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